Drug Profile
Huperzine A
Alternative Names: HupA oral; Huperzine A oral; Qian-ceng-taLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Chinese Academy of Sciences; Mayo Clinic
- Developer Chinese Academy of Sciences; Neuro-Hitech
- Class Alkaloids; Antiepileptic drugs; Neuroprotectants; Nootropics; Sesquiterpenes; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors; Amyloid beta-protein inhibitors; Antioxidants; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Alzheimer's disease
Most Recent Events
- 10 Feb 2011 Discontinued - Phase-II for Alzheimer's disease in USA (PO)
- 05 Feb 2008 Interim efficacy data from the double-blind part of a phase II trial in patients with mild-to-moderate Alzheimer's disease released by Neuro-Hitech
- 15 Dec 2007 Neuro-Hitech completes the double-blind portion of a phase II trial in Alzheimer's disease in USA